Cargando…

The Expression of AQP1 IS Modified in Lung of Patients With Idiopathic Pulmonary Fibrosis: Addressing a Possible New Target

Activation of the epithelial-mesenchymal transition process (EMT) by which alveolar cells in human lung tissue undergo differentiation giving rise to a mesenchymal phenotype (fibroblast/miofibroblasts) has been well recognized as a key element in the origin of idiopathic pulmonary fibrosis (IPF). He...

Descripción completa

Detalles Bibliográficos
Autores principales: Galán-Cobo, Ana, Arellano-Orden, Elena, Sánchez Silva, Rocío, López-Campos, José Luis, Gutiérrez Rivera, César, Gómez Izquierdo, Lourdes, Suárez-Luna, Nela, Molina-Molina, María, Rodríguez Portal, José A., Echevarría, Miriam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5943501/
https://www.ncbi.nlm.nih.gov/pubmed/29774214
http://dx.doi.org/10.3389/fmolb.2018.00043
_version_ 1783321640763916288
author Galán-Cobo, Ana
Arellano-Orden, Elena
Sánchez Silva, Rocío
López-Campos, José Luis
Gutiérrez Rivera, César
Gómez Izquierdo, Lourdes
Suárez-Luna, Nela
Molina-Molina, María
Rodríguez Portal, José A.
Echevarría, Miriam
author_facet Galán-Cobo, Ana
Arellano-Orden, Elena
Sánchez Silva, Rocío
López-Campos, José Luis
Gutiérrez Rivera, César
Gómez Izquierdo, Lourdes
Suárez-Luna, Nela
Molina-Molina, María
Rodríguez Portal, José A.
Echevarría, Miriam
author_sort Galán-Cobo, Ana
collection PubMed
description Activation of the epithelial-mesenchymal transition process (EMT) by which alveolar cells in human lung tissue undergo differentiation giving rise to a mesenchymal phenotype (fibroblast/miofibroblasts) has been well recognized as a key element in the origin of idiopathic pulmonary fibrosis (IPF). Here we analyzed expression of AQP1 in lung biopsies of patients diagnosed with IPF, and compared it to biopsies derived from patients with diverse lung pneumonies, such as hypersensitivity pneumonitis, sarcoidosis or normal lungs. Immunostaining for AQP1 showed a clear increment of AQP1 localized in the alveolar epithelium in biopsies from IPF patients alone. Moreover, to examine the possible participation of AQP1 in the pathophysiology of IPF, we evaluated its role in the pro-fibrotic transformation induced by transforming growth factor (TGF-β) in vitro. Human alveolar epithelial cells (A549), and fibroblasts derived from an IPF patient (LL29), or fibroblasts from healthy normal lung tissue (MRC-5), were treated with TGF-β, and levels of expression of AQP1, as well as those of E-cadherin, vimentin, α-SMA and collagen were analyzed by RT-qPCR, western blot and immunohistochemistry. An increase of AQP1 mRNA and protein after TGF-β treatment (4–72h) was observed either in A549 or IPF fibroblast-LL29 but not in MRC-5 fibroblasts. A gradual reduction of E-cadherin, and increased expression of vimentin, with no changes in α-SMA levels were observed in A549. Whereas in LL29 and MRC-5, TGF-β1 elicited a large production of collagen and α-SMA that was significantly greater in IPF fibroblast-LL29. Changes observed are consistent with activation of EMT by TGF-β, but whether modifications in AQP1 expression are responsible or independent events occurring at the same time is still unknown. Our results suggest that AQP1 plays a role in the pro-fibrotic TGF-β action and contributes to the etiology and pathophysiology of IPF. Understanding AQP1's role will help us comprehend the fate of this disease.
format Online
Article
Text
id pubmed-5943501
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-59435012018-05-17 The Expression of AQP1 IS Modified in Lung of Patients With Idiopathic Pulmonary Fibrosis: Addressing a Possible New Target Galán-Cobo, Ana Arellano-Orden, Elena Sánchez Silva, Rocío López-Campos, José Luis Gutiérrez Rivera, César Gómez Izquierdo, Lourdes Suárez-Luna, Nela Molina-Molina, María Rodríguez Portal, José A. Echevarría, Miriam Front Mol Biosci Molecular Biosciences Activation of the epithelial-mesenchymal transition process (EMT) by which alveolar cells in human lung tissue undergo differentiation giving rise to a mesenchymal phenotype (fibroblast/miofibroblasts) has been well recognized as a key element in the origin of idiopathic pulmonary fibrosis (IPF). Here we analyzed expression of AQP1 in lung biopsies of patients diagnosed with IPF, and compared it to biopsies derived from patients with diverse lung pneumonies, such as hypersensitivity pneumonitis, sarcoidosis or normal lungs. Immunostaining for AQP1 showed a clear increment of AQP1 localized in the alveolar epithelium in biopsies from IPF patients alone. Moreover, to examine the possible participation of AQP1 in the pathophysiology of IPF, we evaluated its role in the pro-fibrotic transformation induced by transforming growth factor (TGF-β) in vitro. Human alveolar epithelial cells (A549), and fibroblasts derived from an IPF patient (LL29), or fibroblasts from healthy normal lung tissue (MRC-5), were treated with TGF-β, and levels of expression of AQP1, as well as those of E-cadherin, vimentin, α-SMA and collagen were analyzed by RT-qPCR, western blot and immunohistochemistry. An increase of AQP1 mRNA and protein after TGF-β treatment (4–72h) was observed either in A549 or IPF fibroblast-LL29 but not in MRC-5 fibroblasts. A gradual reduction of E-cadherin, and increased expression of vimentin, with no changes in α-SMA levels were observed in A549. Whereas in LL29 and MRC-5, TGF-β1 elicited a large production of collagen and α-SMA that was significantly greater in IPF fibroblast-LL29. Changes observed are consistent with activation of EMT by TGF-β, but whether modifications in AQP1 expression are responsible or independent events occurring at the same time is still unknown. Our results suggest that AQP1 plays a role in the pro-fibrotic TGF-β action and contributes to the etiology and pathophysiology of IPF. Understanding AQP1's role will help us comprehend the fate of this disease. Frontiers Media S.A. 2018-05-03 /pmc/articles/PMC5943501/ /pubmed/29774214 http://dx.doi.org/10.3389/fmolb.2018.00043 Text en Copyright © 2018 Galán-Cobo, Arellano-Orden, Sánchez Silva, López-Campos, Gutiérrez Rivera, Gómez Izquierdo, Suárez-Luna, Molina-Molina, Rodríguez Portal and Echevarría. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Molecular Biosciences
Galán-Cobo, Ana
Arellano-Orden, Elena
Sánchez Silva, Rocío
López-Campos, José Luis
Gutiérrez Rivera, César
Gómez Izquierdo, Lourdes
Suárez-Luna, Nela
Molina-Molina, María
Rodríguez Portal, José A.
Echevarría, Miriam
The Expression of AQP1 IS Modified in Lung of Patients With Idiopathic Pulmonary Fibrosis: Addressing a Possible New Target
title The Expression of AQP1 IS Modified in Lung of Patients With Idiopathic Pulmonary Fibrosis: Addressing a Possible New Target
title_full The Expression of AQP1 IS Modified in Lung of Patients With Idiopathic Pulmonary Fibrosis: Addressing a Possible New Target
title_fullStr The Expression of AQP1 IS Modified in Lung of Patients With Idiopathic Pulmonary Fibrosis: Addressing a Possible New Target
title_full_unstemmed The Expression of AQP1 IS Modified in Lung of Patients With Idiopathic Pulmonary Fibrosis: Addressing a Possible New Target
title_short The Expression of AQP1 IS Modified in Lung of Patients With Idiopathic Pulmonary Fibrosis: Addressing a Possible New Target
title_sort expression of aqp1 is modified in lung of patients with idiopathic pulmonary fibrosis: addressing a possible new target
topic Molecular Biosciences
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5943501/
https://www.ncbi.nlm.nih.gov/pubmed/29774214
http://dx.doi.org/10.3389/fmolb.2018.00043
work_keys_str_mv AT galancoboana theexpressionofaqp1ismodifiedinlungofpatientswithidiopathicpulmonaryfibrosisaddressingapossiblenewtarget
AT arellanoordenelena theexpressionofaqp1ismodifiedinlungofpatientswithidiopathicpulmonaryfibrosisaddressingapossiblenewtarget
AT sanchezsilvarocio theexpressionofaqp1ismodifiedinlungofpatientswithidiopathicpulmonaryfibrosisaddressingapossiblenewtarget
AT lopezcamposjoseluis theexpressionofaqp1ismodifiedinlungofpatientswithidiopathicpulmonaryfibrosisaddressingapossiblenewtarget
AT gutierrezriveracesar theexpressionofaqp1ismodifiedinlungofpatientswithidiopathicpulmonaryfibrosisaddressingapossiblenewtarget
AT gomezizquierdolourdes theexpressionofaqp1ismodifiedinlungofpatientswithidiopathicpulmonaryfibrosisaddressingapossiblenewtarget
AT suarezlunanela theexpressionofaqp1ismodifiedinlungofpatientswithidiopathicpulmonaryfibrosisaddressingapossiblenewtarget
AT molinamolinamaria theexpressionofaqp1ismodifiedinlungofpatientswithidiopathicpulmonaryfibrosisaddressingapossiblenewtarget
AT rodriguezportaljosea theexpressionofaqp1ismodifiedinlungofpatientswithidiopathicpulmonaryfibrosisaddressingapossiblenewtarget
AT echevarriamiriam theexpressionofaqp1ismodifiedinlungofpatientswithidiopathicpulmonaryfibrosisaddressingapossiblenewtarget
AT galancoboana expressionofaqp1ismodifiedinlungofpatientswithidiopathicpulmonaryfibrosisaddressingapossiblenewtarget
AT arellanoordenelena expressionofaqp1ismodifiedinlungofpatientswithidiopathicpulmonaryfibrosisaddressingapossiblenewtarget
AT sanchezsilvarocio expressionofaqp1ismodifiedinlungofpatientswithidiopathicpulmonaryfibrosisaddressingapossiblenewtarget
AT lopezcamposjoseluis expressionofaqp1ismodifiedinlungofpatientswithidiopathicpulmonaryfibrosisaddressingapossiblenewtarget
AT gutierrezriveracesar expressionofaqp1ismodifiedinlungofpatientswithidiopathicpulmonaryfibrosisaddressingapossiblenewtarget
AT gomezizquierdolourdes expressionofaqp1ismodifiedinlungofpatientswithidiopathicpulmonaryfibrosisaddressingapossiblenewtarget
AT suarezlunanela expressionofaqp1ismodifiedinlungofpatientswithidiopathicpulmonaryfibrosisaddressingapossiblenewtarget
AT molinamolinamaria expressionofaqp1ismodifiedinlungofpatientswithidiopathicpulmonaryfibrosisaddressingapossiblenewtarget
AT rodriguezportaljosea expressionofaqp1ismodifiedinlungofpatientswithidiopathicpulmonaryfibrosisaddressingapossiblenewtarget
AT echevarriamiriam expressionofaqp1ismodifiedinlungofpatientswithidiopathicpulmonaryfibrosisaddressingapossiblenewtarget